Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

Oxurion NV to Present at the Upcoming Ophthalmology Innovation Summit and Provide a Clinical Update at the American Academy of Ophthalmology 2018 Annual Meeting

24 Oct 2018

Leuven, Belgium, 24 October 2018 – Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced today that Patrik De Haes, M.D., chief executive officer, will present a company overview at the Ophthalmology Innovation Summit (OIS@AAO 2018) at 3:55 p.m. CDT on Thursday, Oct. 25, 2018 in Chicago, Illinois.

The company will also provide an update of its clinical programs at the Subspecialty Day exhibit (booth #18) of the American Academy of Ophthalmology’s 2018 annual meeting (AAO 2018) on Friday, Oct. 26, 2018. During AAO 2018, the company will also be engaging global retina experts by participating in clinical project updates and review meetings.

Furthermore, attendees of AAO 2018 will have the opportunity to meet the Oxurion management team and the company’s US based JETREA® team (ThromboGenics inc booth #4063) at the AAO 2018 exhibition. Physicians who would like to learn more about Oxurion’s US and EU based clinical programs and the recently published peer-reviewed results of the Ocriplasmin Research to Better Inform Treatment (ORBIT) study can meet with Oxurion’s medical experts at the booth.

Additionally, Oxurion will be joining Retina Global as a corporate partner during its industry reception at AAO 2018. The Retina Global Reception will bring together retina specialists, ophthalmologists and industry leaders who are committed to improving treatment options and clinical care for individuals with retinal diseases. The event will take place on Friday, Oct. 26, 2018. For more information, please contact info@retinaglobal.org.

Patrik De Haes, M.D., chief executive officer of Oxurion NV, said: “OIS and AAO 2018 are great opportunities for us to engage with the ophthalmology community in the U.S. and globally. It is an exciting time for Oxurion as we advance our pipeline of disease-modifying drug candidates to preserve vision for patients with back of the eye disorders. We look forward to sharing the progress of our clinical programs in advance of the anticipated study results from our ongoing Phase 1 and Phase 2 clinical trials in the second half of 2019.”

Press release attachment: 
Tags: 
Company